Table 1.
Summary of clinical data (A) and patient numbers in correlative analyses (B).
| (A) | |
|---|---|
| Clinical details | N (%) |
| Age (years)a | 60 (46–83)b |
| ECOGa | |
| 1 | 44 (71) |
| 2 | 18 (29) |
| Platinum responsec | |
| Sensitive/ineligible | 16 (25) |
| Resistant/refractory | 46 (74) |
| Prior lines of therapyb | 3 (1–5) |
| Confirmed BOR | |
| CR | 3 (5) |
| PR | 8 (13) |
| SD | 28 (45) |
| PD | 20 (32) |
| ND | 3 (5) |
| Duration of response (days) | 190 (123–441)b |
| (B) | |
|---|---|
| Correlative analyses | N (%) |
| HRD test | 55 (89) |
| BRCAmut | 60 (97) |
| PD-L1 IHC | 44 (71) |
| RAD51 IHC | 38 (61) |
| BROCA | 52 (84) |
| Oncopanel | 39 (63) |
| Nanostring | 44 (71) |
| CycIF | 26 (37) |
ECOG Eastern Cooperative Oncology Group Performance status, BOR best objective response, CR complete response, PR partial response, SD stable disease, PD progressive disease, ND not defined.
aAt screening.
bMedian (range).
cResponse to last platinum-based chemotherapy.
ECOG; Eastern Cooperative Oncology Group Performance status, BOR; Best objective response, CR; Complete response, PR; Partial response, SD; Stable disease, PD; Progressive disease, ND; Not defined.